Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

Blood

Volumn 124, Issue 9, 2014, Pages 1404-1411

  Dimopoulos, Meletios A ^a   Kastritis, Efstathios ^a   Owen, Roger G ^b   Kyle, Robert A ^c   Landgren, Ola ^d   Morra, Enrica ^e   Leleu, Xavier ^f   García Sanz, Ramón ^g   Munshi, Nikhil ^h   Anderson, Kenneth C ^h   Terpos, Evangelos ^a   Ghobrial, Irene M ^h   Morel, Pierre ⁱ   Maloney, David ^j   Rummel, Mathias ^k   Leblond, Véronique ^l   Advani, Ranjana H ^m   Gertz, Morie A ^c   Kyriakou, Charalampia ⁿ   Thomas, Sheeba K ^o   Barlogie, Bart ^p   Gregory, Stephanie A ^q   Kimby, Eva ^r   Merlini, Giampaolo ^s   Treon, Steven P ^h   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b St James's Institute of Oncology   (United Kingdom)

^c MAYO CLINIC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ Centre Hospitalier de LENS   (France)

^j USA   (United States)

^k UNIVERSITY HOSPITAL GIESSEN   (Germany)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m STANFORD CANCER INSTITUTE   (United States)

ⁿ ROYAL FREE HOSPITAL   (United Kingdom)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^q RUSH UNIVERSITY MEDICAL CENTER   (United States)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s UNIVERSITY OF PAVIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EVEROLIMUS; FLUDARABINE; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CHLORMETHINE DERIVATIVE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE; RAPAMYCIN; VIDARABINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD VISCOSITY; COMORBIDITY; CONSENSUS; CRYOGLOBULINEMIA; CYTOPENIA; DISEASE CONTROL; DISEASE COURSE; FOLLOW UP; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; STRATIFICATION; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; WALDENSTROM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; SALVAGE THERAPY; SIROLIMUS; TREATMENT OUTCOME; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84907365372     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-565135     Document Type: Review

References (59)

1. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol. 2. Geneva: World Health Organization; 2008.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.
3. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2): 116-120.
4. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):121-126.
5. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood. 2006;107(9): 3442-3446.
6. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1): 120-126.
7. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18): 4163-4170.
8. Dimopoulos MA, Kastritis E, Delimpassi S, Zomas A, Kyrtsonis MC, Zervas K. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica. 2008;93(9):1420-1422.
9. Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al; Greek Myeloma Study Group. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res. 2010;34(10):1340-1343.
10. Hivert B, Tamburini J, Vekhoff A, Tournilhac O, Leblond V, Morel P. Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia. Haematologica. 2011;96(5): 785-788.
11. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 2012;119(19):4462-4466.
12. Dhodapkar MV, Hoering A, Gertz MA, et al. Longterm survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Groupdirected intergroup trial S9003. Blood. 2009; 113(4):793-796.
13. Owen RG, Kyle RA, Stone MJ, et al; VIth International Workshop on Waldenström macroglobulinaemia. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171-176.
14. Ghobrial IM, Fonseca R, Greipp PR, et al; Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101(11): 2593-2598.
15. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009;114(12): 2375-2385.
16. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004;15(10): 1481-1483.
17. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007; 13(11):3320-3325.
18. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006; 24(13):2105-2112.
19. Treon S, Tripsas C, Ioakimidis L, et al. Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia [abstract]. Blood. 2011;118. Abstract 2951.
20. Tripsas CK, Meid K, Patterson C, et al. Prospective, multicenter study of the mTor inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia [abstract]. Blood. 2013;122. Abstract 1822.
21. Rummel MJ, Niederle N, Maschmeyer G, et al; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an openlabel, multicentre, randomised, phase 3 noninferiority trial. Lancet. 2013;381(9873): 1203-1210.
22. Rummel MJ, Lerchenmuller C, Greil R, et al. Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenstrom's macroglobulinemia: results from a prospective randomized, multicenter study (StiL NHL 7-2008 -MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214). ASH Annual Meeting Abstracts. 2012;120(21):2739.
23. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leukemia. 2011;11(1): 133-135.
24. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):62-66.
25. Rummel M. Primary therapy of Waldenstrom's macroglobulinemia with Bendamustine Based Therapy. In: 7th International Workshop on Waldenström's Macroglobulinemia; August 23-26, 2012; Newport, RI. Abstract 579.
26. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23): 3830-3835.
27. Ghobrial IM, XieW, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010;85(9): 670-674.
28. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan- prednisonethalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34): 5101-5109.
29. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013; 122(19):3276-3282.
30. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422-1428.
31. San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan- prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31(4):448-455.
32. Tripsas CK, Meid K, Cropper SJ, et al. Carfilzomib, rituximab and dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based therapy in Waldenstrom's macroglobulinemia [abstract]. Blood. 2013;122. Abstract 757.
33. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014;89(3):237-242.
34. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301-307.
35. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012;118(2):434-443.
36. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstr öm macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2): 250-255.
37. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol. 2001;19(16): 3596-3601.
38. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112(12): 4452-4457.
39. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009;15(1): 355-360.
40. Dimopoulos MA, Roussou M, Kastritis E, et al. Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): final analysis of a phase II study. ASH Annual Meeting Abstracts. 2012;120(21):438.
41. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42-51.
42. Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154(3):357-362.
43. Furman RR, Eradat H, DiRienzo CG, et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. ASH Annual Meeting Abstracts. 2011;118(21):3701.
44. Treon SP, Soumerai JD, Hunter ZR, et al. Longterm follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstr öm macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011; 118(2):276-281.
45. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344-3349.
46. Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010; 116(17):3180-3184.
47. Léger JM, Viala K, Nicolas G, et al; RIMAG Study Group (France and Switzerland). Placebocontrolled trial of rituximab in IgM anti-myelinassociated glycoprotein neuropathy. Neurology. 2013;80(24):2217-2225.
48. Hospital MA, Viala K, Dragomir S, et al. Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica. 2013;98(12):e155- e157.
49. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM antimyelin- associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009; 65(3):286-293.
50. Fintelmann F, Forghani R, Schaefer PW, Hochberg EP, Hochberg FH. Bing-Neel Syndrome revisited. Clin Lymphoma Myeloma. 2009;9(1):104-106.
51. Abdallah AO, Atrash S, Muzaffar J, et al. Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature. Clin Lymphoma Myeloma Leukemia. 2013;13(4):502-506.
52. Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood. 2008;112(10):4009-4016.
53. Palladini G, Russo P, Bosoni T, et al. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma. 2009;9(1):80-83.
54. Gertz MA, Buadi FK, Hayman SR. IgM amyloidosis: clinical features in therapeutic outcomes. Clin Lymphoma Myeloma Leuk. 2011; 11(1):146-148.
55. Gertz MA, Hayman SR, Buadi FK. Transplantation for IgM amyloidosis and IgM myeloma. Clin Lymphoma Myeloma. 2009;9(1): 77-79.
56. Palladini G, Foli A, Russo P, et al. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011;11(1):143-145.
57. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28(13):2227-2232.
58. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton's tyrosine kinase in Waldenstrom's macroglobulinemia. Blood. 2013; 122(7):1222-1232.
59. Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013;121(8): 1296-1303.